Magnesium for Preventing Kidney Injury in Mesothelioma Treatment
This study, called MAGIC AKI, is testing if giving intravenous (IV) magnesium sulfate can help prevent acute kidney injury (AKI) in adults with malignant mesothelioma. AKI is a sudden kidney damage that can happen when patients receive intraoperative chemotherapy (HIOC) with cisplatin during surgery. You would receive either magnesium sulfate or normal saline (a saltwater solution) through an IV. Researchers will measure your kidney function daily for 7 days to see if magnesium sulfate helps. This study is for adults aged 18 or older with malignant mesothelioma who are having surgery with HIOC, and who do not have severe kidney problems already.
- Study design
- This is a phase 2, open-label, randomized, placebo-controlled study. About 130 patients will be randomly assigned to receive either magnesium sulfate or normal saline.
- What's involved
- You would be screened for eligibility at your preoperative visit. Intravenous magnesium or saline would be given as a continuous infusion for 24 hours starting during surgery. Blood and urine samples will be collected before and after surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your kidney function will be measured daily for 7 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Shruti Gupta, MD, MPH · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
- David E. Leaf, MD, MMSc · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- AUC of SCr measured daily over 7 days in Mg- versus placebo-treated patients7 days
The primary endpoint is the area under the curve (AUC) of SCr measured daily over 7 days in Mg- versus placebo-treated patients
- Composite Global Rank7 days
As a secondary endpoint, investigators will construct a composite global rank endpoint in which the highest rank is assigned to those who die within 7 days, the second highest rank is assigned to those who survive but require RRT within 7 days, and all others ranked according to their SCr AUC, since RRT and death are important competing risks.